Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Secures $19M BARDA Contract for COVID-19, Combination Assays

NEW YORK — Hologic said Tuesday it has nabbed a $19 million contract from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority for research and development toward gaining regulatory approval for a COVID-19 test and a combination respiratory test.

The Marlborough, Massachusetts-based firm said it will use the money to align its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Aptima SARS-CoV-2 assay with US Food and Drug Administration in vitro diagnostic standards. The combination test is a real-time PCR assay for use with Hologic's Panther Fusion instrument, and the COVID-19-only test is a PCR assay that uses the company's proprietary transcription-mediated amplification chemistry on Panther instruments.

Hologic gained FDA Emergency Use Authorization for the SARS-CoV-2 assay in May 2020. The company secured CE-IVD marking for the combination COVID-19, influenza, and respiratory syncytial virus assay in May 2022 and is working to receive regulatory approval or authorization in the United States.

The BARDA contract is intended to support Hologic's claims related to using nasal swab samples on the Panther Fusion instrument and help the company secure full FDA authorization for the use of its COVID-19 assays on asymptomatic individuals.

In a statement, Kevin Thornal, president of Hologic's Global Diagnostic Solutions group, said "With the help of our tremendous partners at BARDA, and as the pandemic moves to its next phase, we look forward to transitioning COVID testing from EUA to full market authorization, as well as improving the country’s readiness for future pandemics."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.